Renal cell carcinoma (RCC) is the third most common cancer of the urinary system. There is a pressing need for specific biomarkers for advanced/metastatic RCC to enhance diagnostic accuracy and ...

As companies roll out data showing the power and improved safety profile of antibodies that target two antigens, analysts say ...

Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...

2020年5月4日，中山大学附属孙逸仙纪念医院&广东省人民医院在Molecular Cancer (中科院一区 IF=27.7)期刊上在线发表题为 "circNFIB1 inhibits lymphangiogenesis and lymphatic ...

The regulation and remodeling of the tumor microenvironment (TME) are closely associated with how cancers typically progress ...

Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...

TiumBio Co., Ltd. (Kosdaq: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing ...

IGF1R is expressed in a large range of tumors and is crucial for tumor transformation ... growth factors and receptors pathways such as VEGF and EGFR, and IGF1R signaling has been found to ...

Gastric Cancer, Wet (Neovascular / Exudative) Macular Degeneration, Choroidal Neovascularization, Idiopathic Pulmonary Fibrosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), ...

Estrogens have been found to not only fuel the growth of certain breast cancers but also impair immune responses against tumors. Researchers demonstrated that anti-estrogen drugs can restore and ...

AI-081 consists of fully owned and high affinity binding motifs to PD-1 and VEGF that are designed to be best in-class among an emerging class of potentially transformative cancer therapies. We are ...

Cancer Immunology Research publishes outstanding original articles reporting major advances in cancer immunology that span the discipline from basic investigations in host-tumor interactions to ...